國藥(01099.HK)逆市續漲逾7%創逾一年高 國藥集團新冠滅活疫苗國內接種破億劑
國藥控股(01099.HK)逆市四連漲,今天股價更升破去年6月所創52周高位21.8元,最高見22.5元,創逾13個月高,現造22.25元,續漲7.2%,成交急增至2,402萬股,涉資5.26億元。
國藥集團中國生物昨天於微信公眾表示,截至4月12日止,旗下兩個附條件上市新冠滅活疫苗國內接種合共100,176,345劑,未發現與疫苗相關嚴重不良反應。此外,國藥集團中國生物研究院重組新冠病毒疫苗日前獲得國家藥品監督管理局臨床試驗批件,這是繼國藥集團中國生物兩款新冠滅活疫苗後,又一技術路線新冠疫苗獲批臨床,成為中國生物第三款新冠疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.